(Q37263123)

English

Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?

scientific article published on March 2008

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

title

Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? (English)

1 reference

stated in

Europe PubMed Central

19 August 2017

Mark Pegram

1

1 reference

stated in

Europe PubMed Central

PubMed ID

18777951

retrieved

19 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

stated in

Europe PubMed Central

19 August 2017

Clinical Breast Cancer

1 reference

stated in

Europe PubMed Central

19 August 2017

8 Suppl 3

1 reference

stated in

Europe PubMed Central

19 August 2017

S121-30

1 reference

stated in

Europe PubMed Central

19 August 2017

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/J.CCR.2006.10.008

RETRACTED: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1073/PNAS.192569699

Identifiers

DOI

10.3816/CBC.2008.S.008

0 references

PubMed ID

18777951

1 reference

stated in

Europe PubMed Central

PubMed ID

18777951

retrieved

19 August 2017

(Q37263123)

Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)